Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome

Citation:

DOI: http://www.dx.doi.org/10.1371/journal.pone.0016831

© 2011, The Authors
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence

Downloaded from DRO:
http://hdl.handle.net/10536/DRO/DU:30110740
Investigating the Potential Role of Genetic and Epigenetic Variation of DNA Methyltransferase Genes in Hyperplastic Polyposis Syndrome

Musa Drini1,2*, Nicholas C. Wong3, Hamish S. Scott4, Jeffrey M. Craig5, Alexander Dobrovic5,6, Chelsee A. Hewitt5, Christofer Dow7, Joanne P. Young8, Mark A. Jenkins9, Richard Saffery3, Finlay A. Macrae1

1 Colorectal Medicine and Genetics, Royal Melbourne Hospital, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia, 2 Gastroenterology and Hepatology Department, Canberra Hospital, Garran, Australian Capital Territory, Australia, 3 Developmental Epigenetics, Murdoch Childrens Research Institute, Department of Paediatrics, University of Melbourne, Royal Children’s Hospital, Parkville, Victoria, Australia, 4 Institute of Medical and Veterinary Science, Adelaide, Australia, 5 Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, 6 Department of Pathology, University of Melbourne, Parkville, Victoria, Australia, 7 Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia, 8 Queensland Institute of Medical Research, Herston, Queensland, Australia, 9 MEA Epidemiology, School of Population Health, University of Melbourne, Carlton, Victoria, Australia

Abstract

Background: Hyperplastic Polyposis Syndrome (HPS) is a condition associated with multiple serrated polyps, and an increased risk of colorectal cancer (CRC). At least half of CRCs arising in HPS show a CpG island methylator phenotype (CIMP), potentially linked to aberrant DNA methyltransferase (DNMT) activity. CIMP is associated with methylation of tumor suppressor genes including regulators of DNA mismatch repair (such as MLH1, MGMT), and negative regulators of Wnt signaling (such as WIF1). In this study, we investigated the potential for interaction of genetic and epigenetic variation in DNMT genes, in the aetiology of HPS.

Methods: We utilized high resolution melting (HRM) analysis to screen 45 cases with HPS for novel sequence variants in DNMT1, DNMT3A, DNMT3B, and DNMT3L. 21 polyps from 13 patients were screened for BRAF and KRAS mutations, with assessment of promoter methylation in the DNMT1, DNMT3A, DNMT3B, DNMT3L MLH1, MGMT, and WIF1 gene promoters.

Results: No pathologic germline mutations were observed in any DNA-methyltransferase gene. However, the T allele of rs62106244 (intron 10 of DNMT1 gene) was over-represented in cases with HPS (p<0.01) compared with population controls. The DNMT1, DNMT3A and DNMT3B promoters were unmethylated in all instances. Interestingly, the DNMT3L promoter showed low levels of methylation in polyps and normal colonic mucosa relative to matched disease free cells with methylation level negatively correlated to expression level in normal colonic tissue. DNMT3L promoter hypomethylation was more often found in polyps harbouring KRAS mutations (p = 0.0053). BRAF mutations were common (11 out of 21 polyps), whilst KRAS mutations were identified in 4 of 21 polyps.

Conclusions: Genetic or epigenetic alterations in DNMT genes do not appear to be associated with HPS, but further investigation of genetic variation at rs62106244 is justified given the high frequency of the minor allele in this case series.

Introduction

Hyperplastic Polyposis Syndrome (HPS) is a colorectal cancer (CRC) predisposition associated with the development of multiple serrated polyps, and is defined by the World Health Organization as:

(1) at least five serrated polyps proximal to the sigmoid colon with two or more of these being >10 mm; or
(2) any number of serrated polyps proximal to the sigmoid colon in an individual who has a first-degree relative with serrated polyposis; or
(3) >20 serrated polyps of any size, but distributed throughout the colon. The implied meaning of this last criterion is that the polyps are not all present in the rectum [1].

HPS is the genetic disease model for the serrated neoplasia pathway of CRC development [2–4]. This new distinct pathway of CRC is characterized by activating mutation of the BRAF proto-oncogene (specifically V600E) and widespread and concordant gene promoter hypermethylation (CpG Island methylation Phenotype or CIMP) [5–8], and is responsible for silencing of many genes by CpG island methylation in specific cancer subtypes [9]. CIMP positive CRC cancers have distinct clinicopathological features...
including proximal location, mucinous histopathology, female preponderance, and a high frequency of BRAF mutation [7,10–12]. DNA methylation disturbances are also a feature of HPS with a large proportion of BRAF mutation positive HPS polyps being CIMP positive [13,14]. Increased DNA methylation in 14 markers (MINTs 1, 2 and 31, p16, MGMT, MLH1, RASSF1, RASSF2, NORE1, RIKP, MST1, DAPK, FAS and CHFR) in small hyperplastic polyps and in normal mucosa of patients with HPS suggests that there may be a genetic basis for this observation [6].

The aberrant DNA methylation found in the CIMP phenotype may be a consequence of a dysfunction in the machinery involved in establishing and maintaining normal DNA methylation [15]. DNA methyltransferases (DNMTs) are a family of proteins responsible for transfer of methyl groups specifically to cytosine in CpG dinucleotides of DNA [16,17]. Four DNMTs (DNMT1, DNMT3A, DNMT3B, and DNMT3L) are extensively characterized in mammals. DNMT1 acts primarily on hemi-methylated double stranded DNA following DNA replication to faithfully maintain methylation patterns in daughter cells [24,25]. DNMT3A and -3B are involved in de novo methylation, establishing tissue-specific DNA methylation marks during development [26,27]. DNMT3L lacks the methyltransferase catalytic domain [28] and is thought to facilitate the action of other DNMTs by enhancing their targeting to specific loci for DNA methylation [29].

Dysregulation of DNMTs has been linked to many cancers [30], and may play a role in the CIMP phenotype in CRC [31]. Indeed recent evidence suggests that overexpression of DNMT3B in particular shows a significant association with CIMP high CRC [32,33]. Given the observation that even apparently normal mucosa in patients with HPS is highly methylated [6], we investigated the potential for mutation or epigenetic disruption of DNMT1 (CCDS1228.1), DNMT3A (CCDS1718.1), DNMT3B (CCDS13204.1) and DNMT3L (CCDS13705.1) in the development of HPS.

Materials and Methods

Patient Selection

The Melbourne Health Human Research Ethics Committee approved the study (HREC2007.081) and all participants provided written informed consent to take part. We utilized the clinical database of The Royal Melbourne Hospital Bowel Cancer Surveillance Service and the Familial Cancer Clinic, to identify patients satisfying the diagnostic criteria for HPS. Detailed patient demographics, polyp number, size, location, pedigree, family and personal history of CRC and histopathology were prospectively collected (Table 1 and Table 2).

DNA sequence data on this paper have been previously reported on the GenBank database.

Polyps were reviewed by a histopathologist with an interest in the HPS (CD). The use of the term serrated polyph in this report encompasses polyps with serrated architecture and includes microvesicular hyperplastic polyps, and sessile serrated polyps with or without dysplasia. Traditional serrated adenoma and adenoma were not considered in this report. We classified lesions as advanced polyps if the size of the lesion was 10 mm or more.

Control colon tissue was obtained during colonoscopy from patients who presented with abdominal pain for investigation and completed endoscopic examination was normal.

Peripheral blood was collected for germline mutation analysis and immortalized EBV transformed lymphoblast cell lines (LCLs) were generated. If surveillance colonoscopy was performed, polyp tissue was collected and stored in RNAlater (Ambion-Applied Biosystems).

<table>
<thead>
<tr>
<th>Cases</th>
<th>HPs location</th>
<th>Classification of polyps</th>
<th>Size</th>
<th>BRAF/KRAS mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sigmoid colon</td>
<td>SSA</td>
<td>10 mm</td>
<td>KRAS</td>
</tr>
<tr>
<td>2</td>
<td>Descending colon</td>
<td>SSA</td>
<td>8 mm</td>
<td>WT</td>
</tr>
<tr>
<td>3</td>
<td>Rectum</td>
<td>MVHP</td>
<td>5 mm</td>
<td>KRAS</td>
</tr>
<tr>
<td>4</td>
<td>Sigmoid colon</td>
<td>MVHP</td>
<td>9 mm</td>
<td>BRAF</td>
</tr>
<tr>
<td>5</td>
<td>MVHP</td>
<td>5 mm</td>
<td>BRAF</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Rectum</td>
<td>SSA</td>
<td>12 mm</td>
<td>WT</td>
</tr>
<tr>
<td>7</td>
<td>降</td>
<td>SSA</td>
<td>4 mm</td>
<td>BRAF</td>
</tr>
<tr>
<td>8</td>
<td>MVHP</td>
<td>6 mm</td>
<td>BRAF</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>MVHP</td>
<td>5 mm</td>
<td>BRAF</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>MVHP</td>
<td>5 mm</td>
<td>BRAF</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Transverse colon</td>
<td>Mixed HP/SSA</td>
<td>6 mm</td>
<td>WT</td>
</tr>
<tr>
<td>12</td>
<td>SSA</td>
<td>8 mm</td>
<td>BRAF</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>SSA</td>
<td>5 mm</td>
<td>WT</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>SSA</td>
<td>9 mm</td>
<td>BRAF</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>SSA</td>
<td>5 mm</td>
<td>WT</td>
<td></td>
</tr>
</tbody>
</table>

| Table 2. Clinico-pathological characteristics of cases: DNMT promoter methylation analysis and BRAF/KRAS mutation. |

Thirty-six cases from this cohort have been previously reported [66]. CRC-colorectal cancer, FDR-first degree relative.

doi:10.1371/journal.pone.0016831.t002

Total DNA extraction

LCLs (lymphoblast cell lines) were available from 45 patients with HPS. DNA was extracted from all cases using DNeasy 96 Blood and Tissue kits according to the manufacturer’s instructions (Qiagen, Hilden, Germany). In addition, DNA was extracted from...
21 polyps obtained from 13 different HPS cases. DNA concentration and quality was assessed by absorbance spectrophotometry and agarose gel electrophoresis.

RNA Isolation and Real-Time Reverse-Transcription PCR

Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions, followed by treatment with Turbo DNA-free (Ambion/Applied Biosystems, Austin, TX, USA) to remove contaminating genomic DNA. Reverse transcription using random hexamers was performed with SuperScript VILO cDNA Synthesis Kit (Invitrogen). To determine expression levels of genes of interest, quantitative RT-PCR using SYBR Green-based analysis and Master Mix (Invitrogen) was carried out with 10 µM sense and antisense primers (primers on request). Reactions were performed in triplicate and analysed using an ABI 7300 Sequence Detection System (Applied Biosystems). Relative expression levels were determined using the standard ΔΔct method with GAPDH housekeeping gene used for normalisation.

Germline mutation detection

We employed High Resolution Melting (HRM) analysis as a novel and cost effective method to search for the presence of unknown variants in DNMT genes, from 45 cases with available genomic DNA. DNA was first amplified by real time PCR in the presence of LightCycler® 480 High Resolution Melting Dye using a LightCycler® 480 System (Roche Applied Sciences). After the PCR, the successive melting curve experiment was performed in the same apparatus. Gene scanning software was used to identify sequence variation by melt profiling. PCR and DNA melting were performed in triplicate. PCR was optimized with titration of MgCl2 and variation in annealing temperatures. In brief, 10 ng genomic DNA was used in the PCR, Master mix (Roche Applied Sciences), and final forward and reverse primer (concentration 0.2 µM). Sense and antisense PCR primers for DNMT genes were designed using consensus coding sequences: DNMT1 (CCDS12226.1), DNMT3A (CCDS17180.1), DNMT3B (CCDS13284.1) and DNMT3L (CCDS13705) [34]. When amplicon length exceeded 300 bp or nonspecific product was evident following electrophoresis on a 2% agarose gel, we designed alternative primer pairs using the Primer3 software package (http://bioapps.tugraz.at/ primer3_www.cgi). The online POLAND program was used to confirm that amplicons contained a single melting domain [35].

Somatic mutation detection for BRAF and KRAS

High resolution melting (HRM) analysis was performed using a LightCycler® 480 (Roche Diagnostics, Penzberg, Germany) in a modification of the previously published method of [36]. The reaction mixture contained: 1x PCR buffer, DNA template, 200 nM dNTPs (Fisher Biotech Australia, Wembley, Western Australia), 5 µM SYTO® 9 (Invitrogen, Carlsbad, CA), and 0.5 U HotStarTaq polymerase (Qiagen, Germantown, MD, USA). Various concentrations of MgCl2 and primers (primers on request) were used specific to each assay in a 10 µl final reaction volume. PCR reactions were performed in triplicate.

Quantitative DNA methylation analysis by MALDI-TOF MassARRAY EPITYPING and bisulphite sequencing

DNA was extracted from 21 polyps (13 cases with HPS) and 5 controls (colonic mucosa from non-HPS cases) using the DNeasy kit (Qiagen). Bisulfite conversion was performed using the MethylEasy Xceed kit according to manufacturer’s instructions (Human Genetic Signatures, Sydney, Australia) 1–2 µg of genomic DNA was used for bisulphite conversion. The converted DNA was eluted to a final concentration of 20 ng/µl. 20 ng of converted DNA was used for PCR amplification. We employed SEQUENOM EpiTYPER analysis [37] for detection and quantification of DNA methylation of the promoter regions of DNMT1, DNMT3A, DNMT3B and DNMT3L. In brief, genomic DNA was bisulphite treated using MethylEasy Xceed kit (Human Genetic Signatures), PCR amplification was performed using primers directed to the promoter regions of the DNMT genes (primers on request). Amplicons were then subjected to the EpiTYPER chemistry. Briefly, amplicons were treated with shrimp alkaline phosphatase treatment followed by in vitro transcription and base specific cleavage (SEQUENOM, San Diego, CA). Samples were then analysed by MALDI-TOF mass spectroscopy and the methylation ratios obtained using EpiTYPER v1.0.5 software (SEQUENOM). Further analysis and cleaning of data was performed using the R statistical package (http://www.r-project.org) and scripts developed in house. This included identification and removal of CpG units that overlapped with other peaks following mass spectroscopy. Further data cleaning and curation was then performed in R to remove CpG units that did not yield data in at least 70% of samples. Samples, from which less than 40% of CpG units yielded data, were also not included in subsequent analyses.

The DNMT3L amplicons were subjected to cloning and DNA sequencing as outlined in [38]. Amplicons were cloned into pGEMT-Easy Vector (Promega, Madison, WI, USA) and then transformed into DH5α E. coli. Positive clones were selected for automated DNA sequencing performed by the Australian Genome Research Facility (AGRF, Melbourne, Australia). Sequencing data was then analysed using BiQ-Analyzer [39].

Statistical analysis

After data cleaning and curation of SEQUENOM assays, data was analysed using the Heatmap.2 function in R whereby unsupervised hierarchical clustering of the samples and CpG units was performed. Dendrograms and associated heatmaps were generated according to the DNA methylation ratio of specific CpG units and samples analysed. Geometric means methylation levels were calculated for each tissue type, prior to statistical analysis using a Student’s t-test. A box and whisker plot was generated in R to display the distribution of DNA methylation ratios between polyp and germline tissues across the DNMT3L promoter. Calculations were performed to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for the associations between allele frequency and disease. All statistical tests were two-sided and P-value, 0.05 was considered as a significant level of statistical evidence to reject the null hypothesis. All statistical analyses were done using Stata 10.0.

Results

DNA methyltransferase exon scanning by High Resolution Melting (HRM) Analysis

In order to ascertain whether the previously reported methyl-ation disruption associated with HPS may be due to genetic variability in DNMTs, we screened a total of 92 DNMT exons for novel mutations by HRM analysis in LCL genomic DNA from HPS subjects. This comprised 40 exons from DNMT1, 17 from DNMT3A, 24 from DNMT3B and 11 from DNMT3L. We found three previously identified single nucleotide polymorphisms (SNPs) in DNMT1 (synonymous rs721186 and rs2228615) and intronic (rs62106244) and one SNP in DNMT3A (synonymous rs2276598) (Table 3).
The T allele of the rs62106244 C>T variant (Fig. 1) was present in 7 out of 45 cases all of whom were heterozygous. To establish the frequency of this uncharacterised variant in the Caucasian population generally, we scanned 300 control samples, and found 16 that were heterozygous at this site. Chi-square analysis confirmed a statistically significant over representation of both the CT genotype and T allele in HPS cases ($\chi^2 = 6.66$, $p = 0.01$; $\chi^2 = 7.45$, $p<0.01$ respectively). We observed that cases with HPS were approximately three times more likely to carry the variant (15.6%) compared to controls (5.3%), and this difference was statistically significant ($p = 0.01$). However, given the rarity of the variant the confidence intervals were wide (relative risk = 2.9; 95% confidence interval 1.1 to 6.5). DNMT3B and DNMT3L exon scanning did not reveal any SNPs in our HPS cases.

**Table 3. SNPs identified with HRM on germline DNA.**

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP ID</th>
<th>Exon/Intron</th>
<th>DNA change</th>
<th>Clinical association</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNMT1</td>
<td>rs271186</td>
<td>Exon</td>
<td>C&gt;T</td>
<td>Unknown</td>
</tr>
<tr>
<td>DNMT1</td>
<td>rs62106244</td>
<td>Intron</td>
<td>C&gt;T</td>
<td>Unknown</td>
</tr>
<tr>
<td>DNMT3A</td>
<td>rs2228613</td>
<td>Exon</td>
<td>A&gt;C</td>
<td>Unknown</td>
</tr>
<tr>
<td>DNMT3A</td>
<td>rs2276598</td>
<td>Exon</td>
<td>C&gt;T</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

*Seven cases were heterozygous for rs62106244. doi:10.1371/journal.pone.0016831.t003*

Quantitative methylation analysis of CRC CIMP-associated genes and DNMTs

Previous studies using a small number of patients with HPS and methylation specific PCR (MSP) have identified elevated levels of specific promoter methylation in both polyps and normal mucosa relative to non-diseased mucosa from subjects with sporadic serrated polyps [6]. This includes methylation of the MGMT and MLH1 genes. In this study, we measured DNA methylation of the IGF2 differentially methylated region (DMR), H19, MGMT, MLH1 and WIF1 promoters. Contrary to previous reports [40]; [13,14] we found that, MGMT and MLH1 were unmethylated (Fig. S1) in both polyps and matched normal mucosa, while there was no significant difference in DNA methylation of IGF2, H19, and WIF1 (Fig. S1) between polyph and disease free tissue.

In addition to examining CIMP markers, we also examined the potential for methylation based dysregulation of the DNMT genes themselves. Little data is available regarding methylation status of this family of genes in non-diseased somatic tissue, and only limited studies have examined this in disease [41,42]. We studied DNA methylation of the promoter region of the DNMT1, -3A and -3B genes in HPS cases, comparing polyph-derived DNA, normal mucosa from the same patient (where available), and mucosa from controls with no disease. All three promoter regions were generally unmethylated in both polyph and normal mucosal tissue, with less than 10% methylation detected by SEQUENOM Epityper (data not shown). We also found no evidence of promoter methylation of these genes in LCL genomic DNA (data not shown).

Interestingly, we found that DNMT3L was hypomethylated in both normal gut mucosa (mean methylation 0.33, SD 0.24, $n = 12$) and polyph tissue (mean methylation 0.36, SD 0.25 $n = 21$) relative to matched LCL DNA (mean 0.57, SD 0.24 $n = 19$); see unsupervised clustering figure 2A and box and whisker plot figure 2B). This difference was highly significant ($p = 5.1 \times 10^{-9}$ Student’s $t$-test) and was confirmed by bisulphite sequencing (Fig. 3). We were unable to test expression level directly in HPS samples due to a lack of RNA, however a negative correlation between mean methylation and expression level was found in normal colonic tissue ($R = −0.64$; Fig. 4).

**KRAS** mutation may correlate with DNMT3L promoter methylation

CIMP and **BRAF** mutation are hallmarks of serrated tumours and **BRAF** V600E has been proposed as an important biological marker for HPS specific cancers [43]. We performed **BRAF** (V600E) and **KRAS** screening with HRM on DNA from serrated polyps derived from HPS cases and controls. Consistent with previous published data [7,44] we found that the **BRAF** V600E mutation was common in serrated polyps (11 out of 21) whereas the **KRAS** mutation was evident in only 4 out of 21. **KRAS** mutations were found primarily in polyps located in the transverse colon (two) and rectum (two). Interestingly one patient had two polyps with the **BRAF** somatic mutation and one with the **KRAS** somatic mutation, all within the right colon from the same patient. Examination of the level of DNMT3L promoter methylation and **KRAS** mutation-containing polyps revealed an association between these distinct genetic and epigenetic modifications (Table 4).

Polyps with **KRAS** mutations were far more likely to show DNMT3L promoter methylation at levels similar to those found in LCLs ($p = 0.0053$). In contrast, polyps with the **BRAF** mutation did not show any significant association with DNMT3L promoter methylation.
Discussion

Given the significant association of HPS and associated tumours with increasing levels of aberrant promoter methylation (CIMP), including extensive methylation in the normal mucosa, and the role of DNMTs in both the establishment and maintenance of DNA methylation in humans, we examined the potential association of genetic and epigenetic disruption of DNMTs in HPS.

Genetic variation is the DNMT1 gene is potentially associated with HPS

Variants in DNMT1 have been identified as risk factors for disease including systemic lupus erythematosus [45]. Genetic deficiency of DNMT3B causes ICF syndrome, a recessive human disorder characterised by immunodeficiency, centromere instability, and facial anomalies [46]. Variants in other DNMTs (i.e. DNMT3L, DNMT1) have been associated with human cancers [47–50]. Recently, a rare variant of DNMT3L was specifically associated with reduced methylation of sub-telomeric regions in humans [51]. In this study we demonstrated that HPS is not
associated with germline mutations of the *DNMT3A, 3B, or 3L* genes. Although we identified SNPs in both *DNMT1* and *DNMT3A* in HPS cases, these were generally detected at similar frequencies in non-diseased subjects and were predicted to be non-pathogenic.

The exception was rs62106244, located in the *DNMT1* gene, that was found to have a significantly higher frequency in HPS cases in comparison with controls. This SNP is not predicted to alter *DNMT1* splicing or protein, and is not evolutionarily conserved beyond primates [52]. Corresponding intronic SNPs, in other genes, have previously been associated with many diseases, including some cancers [53]. In fact as many as 45% of all trait/disease-associated SNPs identified in genome-wide association studies are intronic [54] with the pathogenic mechanisms underlying such associations remaining largely unclear. In addition, the level of linkage disequilibrium (LD) of rs62106244 in relation to other variants (i.e. haplotype status) has not yet been determined, although the entire *DNMT1* gene lies in a large block of LD.

**Common CIMP markers are absent in most HPS lesions**

**Perturbation of DNA methylation and loss of gene function is well documented in MSI-H CRC [55]. However, the role of aberrant DNA methylation in precancerous lesions remains poorly understood despite its widespread occurrence. It has been reported that alteration of DNA methylation in hepatocellular carcinoma (HCC) evolves through precancerous lesions to multistage hepatocarcinogenesis [56]. In comparison with non-diseased tissue, human cancers generally show variations in both global DNA methylation (hypomethylation) and gene-specific (hyper- or hypo methylation) status [16,57].**

Promoter methylation of *MLH1* in MSI-H sporadic colon cancers represents a classical example of aberrant methylation leading to cancer [12]. We did not find any evidence of aberrant methylation in HPS “precancerous lesions” for this traditional CIMP marker or for the *MGMT* gene. DNA methylation at other markers (*EGF2, WiFi1* and *H19*) was also found to be unaffected in this group of HPS cases. *MLH1* methylation is associated with high-level MSI and this is in turn usually observed in areas of dysplasia or overt carcinoma. Similarly, methylation of *MGMT* is more likely to be seen in conjunction with *KRAS* mutation. Our findings in polyps therefore are not inconsistent with published reports.

**DNMT3L is specifically hypomethylated in gut mucosa and HPS**

Our data from a candidate gene approach to explore epigenetic abnormalities in HPS revealed a general lack of *DNMT1*, *DNMT3A* and *DNMT3B* methylation as expected in non-diseased mucosal tissue. However, *DNMT3L* usually silenced in somatic tissues by methylation, was found to be *hypomethylated* in both HPS polyps and normal gut mucosa relative to LCLs. There was no statistically significant difference between matched normal mucosa and polyps derived from the same cases, or between colonic mucosa from HPS cases and controls (colonic mucosa from cases with normal endoscopic findings and no history of polyps). We also found elevated methylation levels in all other somatic tissues tested including kidney, peripheral blood mononuclear cells, skeletal muscle, brain, and skin fibroblasts (data not shown), suggesting that the decreased methylation seen in gut mucosa is of functional significance. This was further supported by gene expression analysis that confirmed a inverse correlation between mean methylation and gene expression levels. In mice, methylation of the *DNMT3L* promoter has been unequivocally linked to gene silencing [58], and it has been shown that this gene is primarily expressed in thymus, testis and ovaries [23,59]. We have now added gut mucosa to the list of tissues expressing this gene. Recently the loss of DNA methylation at the *DNMT3L* promoter was found to be a positive biomarker for cervical cancer [60]. *DNMT3L* over expression in cervical cancer cells increases cellular proliferation, anchorage independent growth and nuclear reprogramming of cells, all central events in tumour development [61].

**An interaction between DNMT3L methylation and KRAS mutation?**

Previous studies that have examined the relationship between *BRAF* and *KRAS* mutations in a wide range of colonic polyp and cancer tissue have found a mutually exclusive distribution of these mutations [7]. *DNMT3L* methylation percentage across all CpG sites analysed for cases with *BRAF* and *KRAS* mutation revealed increased methylation of the *DNMT3L* promoter in cases with a *KRAS* mutation when compared with polyps with the normal variant (p = 0.0053), however due to small number of cases this observation need not be investigated in a larger number of polyps harbouring *KRAS* mutation. Additionally we found both *BRAF* and *KRAS* mutations in a single case (two polyps harbouring *BRAF* mutation and one polyp with *KRAS* mutation), which, though relatively rare, has been previously described [44]. Lesions harbouring *KRAS* mutations have been associated with distal location within the colorectum [62] MSI-L status [63] and unfavourable prognosis [64]. Our findings with regard to *DNMT3L* methylation and *KRAS* mutation need to be investigated further as recently aberrant promoter hypomethylation of *DNMT3L* has been linked with cervical cancer tumorigenesis [60]. The increased *DNMT3L* methylation seen in *KRAS* mutated.

### Table 4. Quantitative methylation (%) of DNMT gene promoters: 21 serrated polyps stratified by BRAF and KRAS mutation.

<table>
<thead>
<tr>
<th></th>
<th>Mean <em>DNMT1</em> methylation (%)</th>
<th>Mean <em>DNMT3A</em> methylation (%)</th>
<th>Mean <em>DNMT3B</em> methylation (%)</th>
<th>Mean <em>DNMT3L</em> methylation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyps with <em>BRAF</em> mutation</td>
<td>3.3*</td>
<td>4.3*</td>
<td>21*</td>
<td>37*</td>
</tr>
<tr>
<td>Polyps with <em>KRAS</em> mutation</td>
<td>2.8*</td>
<td>4.1*</td>
<td>27*</td>
<td>55**</td>
</tr>
<tr>
<td>Polyps WT for <em>BRAF</em> and <em>KRAS</em></td>
<td>3.6</td>
<td>4.4</td>
<td>25</td>
<td>30</td>
</tr>
</tbody>
</table>

*p-value* <0.05 for *DNMT1, DNMT3A* and *DNMT3B*.
*p-value* = 0.147 (*BRAF*/WT).
**p-value** = 0.0053 (*KRAS*/WT).
polyps is commensurate with the lower levels of methylation generally seen in these polyps relative to those with BRAF mutations.

Conclusions
To date, there is no single genetic abnormality known to underlie HPS. In addition, factors determining the transition to colon carcinoma remain unknown. There have been several reports implicating DNMT dysregulation in carcinogenesis [41,65]. However, the degree to which DNMTs may contribute to the development of precancerous lesions remains poorly understood. This study represents the first investigation of the possible role of the DNMT family of genes in the development of HPS. The data generated do not exclude a functional role of DNMT dysregulation in the development of HPS and associated disorders, however no exonic germline mutations were discovered, suggesting that regulation of DNMTs may occur via alternative mechanisms in this condition. It is interesting to speculate that the observed hypomethylation of the DNMT3L promoter in normal gut mucosa in the HPS patients identified here, may also play a role in the aberrant de novo establishment of tumour suppressor methylation seen in most CRCs.

Supporting Information
Figure S1 Quantitative methylation analysis (%) with SEQUENCE-NOM: genes analysed H19, MGMT, MLH1, WIF1, BRAF and KRAS. Samples: S1, S13, S10, S11 and S26 were disease free tissue. (TIF)

Acknowledgments
We thank Dr Justine Ellis and Dr Lavinia Gordon for help with statistical analysis.

Author Contributions
Conceived and designed the experiments: MD NCW HSS JPY. Performed the experiments: MD NCW HSS CAH RS. Analyzed the data: MD NCW RS JMC HSS AD JPY. Contributed reagents/materials/analysis tools: RS JMC HSS. Wrote the manuscript: MD NCW HSS RS JMC HSS AD. Made polys histopathology assessment: CD. Contributed on biostatistics with regard to data analysis and critical review of manuscript: MAJ.

References


